Financial Performance - Operating revenue for the first quarter of 2023 was CNY 51,045,814.36, representing a year-on-year growth of 27.85%[10] - Net profit attributable to shareholders for the first quarter of 2023 was CNY 7,684,095.67, up 33.17% from the same period last year[10] - The net profit margin for the first quarter of 2023 was approximately 15.08%, reflecting improved profitability[10] - Total operating revenue for Q1 2023 reached ¥51,045,814.36, a significant increase from ¥39,927,026.95 in Q1 2022, representing a growth of approximately 28.1%[54] - Net profit for Q1 2023 was ¥7,684,095.67, up from ¥5,770,196.79 in Q1 2022, reflecting a growth of approximately 33.3%[56] - The total comprehensive income amounted to 7,982,611.80, compared to 5,770,196.79 in the previous year[60] Assets and Liabilities - Total assets as of March 31, 2023, reached CNY 442,797,535.41, an increase of 2.03% compared to the end of 2022[10] - Total liabilities amounted to CNY 153,059,579.47, slightly up from CNY 152,040,697.45, reflecting a marginal increase of 0.67%[48] - Shareholders' equity reached CNY 289,737,955.94, compared to CNY 281,951,875.27, marking an increase of approximately 2.78%[48] - Current assets totaled CNY 357,241,080.85, an increase from CNY 347,271,541.50, reflecting a growth of about 2.83%[46] - Total assets at the end of the reporting period were ¥412,018,697.07, up from ¥403,055,478.26, reflecting a growth of about 2.4%[52] Cash Flow - The net cash flow from operating activities decreased by 128.79% to CNY -2,818,387.26 compared to the previous year[11] - Cash inflow from operating activities was 41,317,783.97, down from 45,804,214.16 in the same period last year, representing a decrease of approximately 9.7%[61] - Total cash outflow from operating activities was 44,136,171.23, compared to 36,013,677.83 in the previous year, indicating an increase of about 22.6%[63] - Cash and cash equivalents decreased to CNY 152,264,619.45 from CNY 178,406,927.66, a decline of approximately 14.65%[46] Expenses - Research and development expenses for the first quarter of 2023 amounted to CNY 136,420.00, a decrease of 35.48% year-on-year[14] - Sales expenses increased by 187.72% to CNY 4,516,200.00 due to increased marketing activities[14] - Total operating costs for Q1 2023 were ¥42,403,116.82, compared to ¥33,655,772.00 in Q1 2022, indicating an increase of about 26.0%[55] - Research and development expenses for Q1 2023 were ¥1,364,229.54, down from ¥2,114,302.53 in Q1 2022, indicating a reduction of approximately 35.3%[55] Shareholder Information - The total number of unrestricted shares decreased from 22,753,221 to 22,691,646, representing a change of -61,575 shares, which is a decrease of approximately 0.27%[22] - The total number of restricted shares increased from 45,746,779 to 45,808,354, representing a change of 61,575 shares, which is an increase of approximately 0.13%[22] - The largest shareholder, Bi Chunguang, holds 18,301,266 shares, accounting for 26.72% of the total shares[25] - The second largest shareholder, Bianjing, holds 13,596,309 shares, accounting for 19.85% of the total shares[25] - The top ten shareholders collectively hold 47,663,280 shares, which is 69.60% of the total shares[25] Commitments and Guarantees - The company has provided guarantees totaling 27,900,000 CNY for loans, with a remaining guarantee balance of 26,900,000 CNY[31] - The company applied for a loan of 9 million CNY from China Everbright Bank, with a guarantee provided by a related party[32] - The company applied for a loan of 5 million CNY from CITIC Bank, with a guarantee provided by the actual controller[32] - The actual controller has committed to not occupying company funds since February 2016, and this commitment is currently being fulfilled[34] - The company has established internal control measures to prevent fund occupation or asset transfer by shareholders and related parties[36] Compliance and Regulatory Matters - The company guarantees that its issuance application documents do not contain false records or misleading statements, and will initiate a share buyback if such issues are identified[39] - The company will disclose specific reasons for any failure to fulfill commitments in a timely manner[39] - The company will ensure compliance with relevant laws and regulations in handling any non-fulfillment of commitments[39] - The company will publicly disclose reasons for any failure to fulfill commitments and apologize to shareholders and the public[38]
春光药装(838810) - 2023 Q1 - 季度财报